ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Hepatocellular carcinoma"

  • 2021 American Transplant Congress

    Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era

    K. Okumura, H. Sogawa, G. Veillette, D. John, T. Diflo, R. Bodin, D. C. Wolf, S. Nishida

    Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY

    *Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…
  • 2021 American Transplant Congress

    The Role of Histone Acetylation/methylation Mediated Epigenetic Modifications in the Pathogenesis of Non-alcoholic Steatohepatitis-associated Liver Carcinogenesis

    P. K. Rajan1, U. Utibe-Abasi1, J. D. Sanabria1, M. Banerjee2, G. Smith1, M. S. Schade1, J. Sanabria1, K. Sodhi1, S. Pierre2, Z. Xie2, J. I. Shapiro2, J. Sanabria1

    1Department of Surgery, Marshall University, Huntington, WV, 2Marshall Institute for Interdisciplinary Research (MIIR), Marshall University, Huntington, WV

    *Purpose: Hepatocellular carcinoma (HCC) is one of the most aggressive human cancers and is characterized by an acquisition of multiple abnormal phenotypes driven by epigenetic…
  • 2021 American Transplant Congress

    Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything

    G. T. Schnickel1, J. Parekh1, Y. Kono2, J. Berumen1, V. Ajmeera2, K. Mekeel1

    1Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego, San Diego, CA, 2Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA

    *Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…
  • 2021 American Transplant Congress

    Outcomes of Downstaging Hepatocellular Carcinoma (HCC) to within Milan Criteria Before Liver Transplantation (LT): A Multicenter Analysis of the “All-comers” Protocol

    B. Natarajan1, P. Tabrizian2, M. Hoteit3, C. Frenette4, T. Ghaziani5, R. Dhanasekaran5, N. Parikh6, J. Guy7, A. Shui1, S. Florman2, F. Yao1, N. Mehta1

    1UCSF, SF, CA, 2Mt Sinai, NY, NY, 3U Penn, Philadelphia, PA, 4Scripps, La Jolla, CA, 5Stanford, Palo Alto, CA, 6U Michigan, Ann Arbor, MI, 7CPMC, SF, CA

    *Purpose: Patients with HCC meeting UNOS-downstaging (DS) criteria (1 lesion 5.1-8 cm, 2-3 lesions at least one 3.1-5 cm and total tumor diameter (TTD) ≤8…
  • 2021 American Transplant Congress

    Albumin Level Prior to Liver-Directed Therapy is a Risk Factor of Waitlist Tumor Progression Independent of HCC Burden

    P. Thevenot, K. Nunez, T. Sandow, M. Hibino, P. Wright, J. Patel, D. Fort, A. Cohen

    Ochsner Health, New Orleans, LA

    *Purpose: Milan Criteria, α-fetoprotein (AFP), and MELD score at diagnosis influence prognosis in bridge to transplant (BTT) hepatocellular carcinoma (HCC). With HCC surveillance many patients…
  • 2021 American Transplant Congress

    Role of Baseline PD-1 Checkpoint Inhibitor Pathway Expression in Bridge to Liver Transplant Hepatocellular Carcinoma

    K. Nunez, T. Sandow, M. Hibino, A. Cohen, P. Thevenot

    Ochsner Health, New Orleans, LA

    *Purpose: Response to first line liver-directed therapy (LDT) in hepatocellular carcinoma (HCC) has important implications in both bridge to transplant (BTT) success as well as…
  • 2021 American Transplant Congress

    Short Waiting Time is Not Associated with Decrease in Disease-free Survival in Liver Transplant Recipients with HCC

    J. Daum1, N. Gupta1, B. Aqel2, L. Mi3, J. Harbell4

    1School of Medicine, Mayo Clinic Arizona, Phoenix, AZ, 2Hepatology, Mayo Clinic Arizona, Phoenix, AZ, 3Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, 4Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ

    *Purpose: Studies have suggested that shorter waiting times (WT) for liver transplant (LT) in patients with hepatocellular carcinoma (HCC) may be associated with increased HCC…
  • 2021 American Transplant Congress

    NASH-Related HCC is Associated with Lower Rates of Post-Transplant HCC Recurrence: A Large Database Analysis

    P. J. Altshuler, R. Lamm, K. Patel, H. Dang, O. Shaheen, A. P. Shah, J. Glorioso, C. G. Ramirez, A. M. Frank, W. R. Maley, A. S. Bodzin

    Department of Surgery, Thomas Jefferson University, Philadelphia, PA

    *Purpose: As incidence of hepatocellular carcinoma (HCC) and Non-Alcoholic Steatohepatitis (NASH) increase, NASH-related HCC is an increasingly common transplant indication. Large-scale studies evaluating transplantation for…
  • 2021 American Transplant Congress

    Outcomes of DCD Allografts in Liver Transplant Recipients with HCC

    N. Gupta1, J. Daum1, B. Aqel2, L. Mi3, J. Harbell4

    1School of Medicine, Mayo Clinic Arizona, Phoenix, AZ, 2Hepatology, Mayo Clinic Arizona, Phoenix, AZ, 3Biostatistics, Mayo Clinic Arizona, Phoenix, AZ, 4Transplant Surgery, Mayo Clinic Arizona, Phoenix, AZ

    *Purpose: Early studies demonstrated inferior survival for liver transplant (LT) recipients with hepatocellular carcinoma (HCC) who received allografts from donation after cardiac death (DCD) donors…
  • 2021 American Transplant Congress

    Adjuvant Immunotherapy for Liver Transplant Recipients with Hepatocellular Carcinoma Using Donor Liver-derived Natural Killer Cells

    M. Ohira1, R. Hotta1, Y. Imaoka1, K. Sato1, N. Tanimine1, Y. Tanaka1, S. Nishida2, A. Tzakis2, H. Ohdan1

    1Hiroshima University, Hiroshima, Japan, 2University of Miami, Miami, FL

    *Purpose: Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and is an indication for liver transplantation (LT). Immunosuppressive regimens currently used after…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 23
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences